Drugdiscovery >> Drugs >> News
8769
Views
Novartis muscle drug gets breakthrough therapy designation - drugdiscovery.com
Novartis muscle drug gets breakthrough therapy designation - drugdiscovery.com


The FDA granted a breakthrough therapy status to Novartis’ newly developed compound- bimagrumab (BYM338), used to treat a life-threatening muscle disease called sporadic inclusion body myositis that causes patients’ muscles to waste away. The drug is also indicated for treatment of patients with obstructive pulmonary disease (COPD), cancer cachexia, and sarcopenia, as well as mechanically ventilated patients.
Read More >>


Tags: Novartis, cancer cachexia,sarcopenia, COPD, bimagrumab, BYM338, sporadic inclusion body myositis, muscles, waste away - August 21, 2013
Related Articles
5510
Views
Breakthrough Therapy designation for leukemia drug Arzerra Breakthrough Therapy designation for leukemia drug Arzerra
The FDA has granted Breakthrough Therapy designation for the drug Arzerra (ofatumumab), co-development by Genamb and GSK, used in combination with chlorambucil for the treatment of patients with chro Read More >>

Tags: Arzerra, ofatumumab, chronic lymphocytic leukemia, CLL, breakthrough therapy designation

16126
Views
Breakthrough therapy designation for Roche’s lung cancer drug alectinib Breakthrough therapy designation for Roche’s lung cancer drug alectinib
The FDA has granted breakthrough therapy designation for Roche’s promising investigational 2nd generation ALK inhibitor, used for the treatment of patients with metastatic non-small cell lung cance Read More >>

Tags: alectinib, lung cancer, breakthrough therapy designation, Roche, investigational drug, ALK inhibitor, metastatic non-small cell lung cancer, NSCLC, FDA

6007
Views
Breakthrough Therapy Designation for Firdapse Breakthrough Therapy Designation for Firdapse
FDA has granted a Breakthrough Therapy Designation to Catalyst Pharmaceutical Partners for the drug Firdapse (amifampridine phosphate), for the symptomatic treatment of patients with Lambert-Eaton Mya Read More >>

Tags: Firdapse, Lambert-Eaton Myasthenic Syndrome, LEMS, orphan drug, breakthrough therapy

3323
Views
Breakthrough Therapy designation for AML drug volasertib Breakthrough Therapy designation for AML drug volasertib
The FDA has granted Breakthrough Therapy designation to Boehringer Ingelheim’s investigational compound - volasertib, for the treatment of patients with acute myeloid leukemia. Read More >>

Tags: volasertib, acute myeloid leukemia, Boehringer Ingelheim, breakthrough therapy,experimental drug

6114
Views
Orphan Drug Designation for ReN003 retinal stem cell therapy Orphan Drug Designation for ReN003 retinal stem cell therapy
ReNeuron Group’s ReN003 retinal stem cell therapy, candidate for retinitis pigmentosa, has been granted Orphan Drug Designation in both Europe and the U.S. Read More >>

Tags: Orphan Drug Designation, ReN003, retinal stem cell therapy, retinitis pigmentosa, orphan drug, stem cell therapy

6603
Views
Cancer muscle wasting drug fails in late stage clinical trial Cancer muscle wasting drug fails in late stage clinical trial
GTx ‘drug enobosarm is designed to prevent or treat muscle wasting in cancer patients. Currently, there are no drugs approved for treatment of this condition. In a late-stage clinical trial in patie Read More >>

Tags: muscle wasting, drug, cancer, enobosarm, GTx, cancer cachexia

7916
Views
Orphan drug designation for Delcath’s liver cancer drug Orphan drug designation for Delcath’s liver cancer drug
The FDA has granted "orphan drug" status to Delcath Systems’ melphalan hidrochloride chemotherapy for the treatment of primary liver cancer (hepatocellular carcinoma). Read More >>

Tags: melphalan, liver cancer, US, orphan drug, designation, hepatocellular carcinoma, Delcath

5320
Views
Novartis AG drug might be a blockbuster - late stage test proved Novartis AG drug might be a blockbuster - late stage test proved
Jakavi, ruxolitinib drug of Novartis has produced nice results in patients with myelofibrosis. Patients with at least years of treatment said that their life quality improved significantly. Read More >>

Tags: Novartis, myelofibrosis, Jakavi, late-stage

5578
Views
Orphan drug designation for Bayer’s hypertension drug riociguat Orphan drug designation for Bayer’s hypertension drug riociguat
The FDA has granted two separate orphan drug designations for riociguat, Bayer’s investigational hypertension drug, for the treatment of pulmonary arterial hypertension and chronic thromboembolic pu Read More >>

Tags: riociguat, hypertension, drug, orphan drug designation, orphan, Bayer, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension

5468
Views
Priority Review designation for Nexavar Priority Review designation for Nexavar
FDA has granted Priority Review designation for the Bayer HealthCare’s and Onyx Pharmaceuticals’ oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of local Read More >>

Tags: Nexavar, sorafenib, thyroid cancer, advanced, Bayer HealthCare, Onyx Pharmaceuticals, priority review designation, FDA

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013